Compare FRPH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | OMER |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 844.6M |
| IPO Year | 1995 | 2008 |
| Metric | FRPH | OMER |
|---|---|---|
| Price | $21.11 | $20.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 93.7K | ★ 1.5M |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $42,846,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $26.14 |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $20.53 | $4.06 |
| 52 Week High | $25.74 | $21.24 |
| Indicator | FRPH | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 61.99 |
| Support Level | $20.78 | $18.00 |
| Resistance Level | $23.10 | N/A |
| Average True Range (ATR) | 0.46 | 0.88 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 7.69 | 73.95 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.